Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Organisation › Details

Galapagos N.V. (Euronext + Nasdaq: GLPG)

Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *

 

Period Start 1999-06-01 established_pre
  Group Galapagos (Group)
  Predecessor Galapagos Genomics N.V.
Product Industry genomics/genetics
Persons Person Stoffels, Paul (Galapagos 202204– CEO before JnJ + Virco + Tibotec)
  Person 2 Huston, Thad (Galapagos 202307– CFO + COO before Kite + LivaNova + 25y at JnJ)
     
Region Region Mechelen
  Country Belgium
  Street Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3
  City 2800 Mechelen
  Tel +32-15342900
    Address record changed: 2020-12-02
     
Basic data Employees F: 1,001 to 5,000 (2019-12-31)
  Currency EUR
  Annual sales 895,890,000 (revenues + other income, total, consolidated (2019) 2019-12-31)
  Profit 149,845,000 (2019-12-31)
  Cash 5,780,832,000 (2019-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-06-04

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x300px




» top